TriangleNCT03944057 · OUTCOME
Progression-Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- month
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 12 months
What was measured
To evaluate progression-free survival
Groups in this outcome
ATG-010 + Dexamethasone
Open-label ATG-010 80mg plus Dexamethasone 20 mg ATG-010: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
| Group | Source count |
|---|---|
| ATG-010 + Dexamethasone | 82 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ATG-010 + Dexamethasone | 3.7 | Not reported | 2.02 | 4.66 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.02
- upper Limit
- 4.66
- value
- 3.7
- denoms
- counts
- group Id
- OG000
- value
- 82
- units
- Participants
- description
- To evaluate progression-free survival
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Open-label ATG-010 80mg plus Dexamethasone 20 mg ATG-010: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
- id
- OG000
- title
- ATG-010 + Dexamethasone
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 12 months
- title
- Progression-Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- month
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice